Junshi’s Toripalimab Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Nasopharyngeal Carcinoma

 Junshi’s Toripalimab Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Nasopharyngeal Carcinoma

Junshi’s Toripalimab Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Nasopharyngeal Carcinoma

Shots:

  • The US FDA has granted the BTD for Toripalimab to treat nasopharyngeal carcinoma. The BTD will allow the company to work with the FDA to bring the therapy to patients worldwide expeditiously
  • The US FDA’s BTD for the therapy supports and accelerate the commercial development plan of Toripalimab in the US
  • Toripalimab is the 1st anti-PD-1 Ab to receive the BTD in China, it marks another regulatory milestone after FDA granted ODD in May’2020

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: GlobeNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post